NCT07184619: Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
- State
- Under way
- Phase
- Phase 3
- People
- 400 planned
- Started
- 23 Jan 2026
- Primary completion
- 31 Mar 2027
- Arms
- Evenamide 15 mg bid
- Results
- None posted
- 22 Sep 2025: Trial registered
- 23 Jan 2026: Trial started